$NVO more pain ahead! Headed down to $46-55
- 
NVO was one of the hottest stocks of 2024 is now facing immense challenges by other healthcare companies in weight loss drug.
- With weak results, it sets up for disappointment for 1-2 quarters. Quick turnaround in experiments isn't feasible and would need considerable time to show promising results.
- It's better to put it on watchlist, attend earning call however it is likely that it might underperform FY 2025 or alteast first half of FY 2025.
NVO was one of the hottest stocks of 2024 is now facing immense challenges by other healthcare companies in weight loss drug. - With weak results, it sets up for disappointment for 1-2 quarters. Quick turnaround in experiments isn't feasible and would need considerable time to show promising results.
- It's better to put it on watchlist, attend earning call however it is likely that it might underperform FY 2025 or alteast first half of FY 2025.
Trading ditutup secara manual
Earnings were promising; riding the upside!Catatan
This is reversing real quick. Monitoring it closely if it takes down 52 weeks low or not!Catatan
HIMS superbowl ad scared weight loss drug makers
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.